IRIDEX Corporation (NASDAQ:IRIX – Get Free Report) major shareholder Shih-Yao David Lin purchased 19,324 shares of IRIDEX stock in a transaction that occurred on Wednesday, February 4th. The shares were bought at an average price of $1.41 per share, for a total transaction of $27,246.84. Following the transaction, the insider owned 1,058,323 shares in the company, valued at $1,492,235.43. This represents a 1.86% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
IRIDEX Trading Up 2.2%
IRIX opened at $0.90 on Friday. IRIDEX Corporation has a 1-year low of $0.61 and a 1-year high of $1.65. The stock has a market capitalization of $15.78 million, a PE ratio of -4.49 and a beta of 0.67. The firm has a 50-day moving average price of $0.73 and a two-hundred day moving average price of $0.95.
IRIDEX (NASDAQ:IRIX – Get Free Report) last issued its quarterly earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06). The company had revenue of $12.57 million for the quarter, compared to analyst estimates of $13.59 million. On average, research analysts predict that IRIDEX Corporation will post -0.12 EPS for the current year.
Analyst Ratings Changes
Check Out Our Latest Stock Analysis on IRIDEX
Trending Headlines about IRIDEX
Here are the key news stories impacting IRIDEX this week:
- Positive Sentiment: Lin reported another purchase of 10,000 IRIX shares at an average price of $1.05, worth $10,500. The transaction increased his direct holdings to 735,561 shares. IRIDEX major shareholder buys 10,000 shares
- Positive Sentiment: SEC disclosures show a sustained accumulation campaign by Lin, including purchases of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00, along with numerous other transactions. Repeated buying by a major shareholder may signal confidence in IRIDEX’s longer-term prospects and can support momentum in a low-market-cap stock. IRIDEX major shareholder buys 50,000 shares
- Positive Sentiment: Several institutional investors also increased positions, including Perkins Capital Management, Thompson Davis, and Renaissance Technologies. Institutions own approximately 20.1% of IRIDEX’s shares, providing additional ownership support, though their disclosed positions remain relatively small in dollar terms.
- Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down pause. The halt underscores unusually high volatility and the possibility of sharp price reversals when trading resumes.
- Neutral Sentiment: Analyst sentiment remains mixed: one analyst rates the stock Buy and another Sell, resulting in a consensus Hold rating. The reported consensus price target is $3.00, but the limited coverage reduces its reliability.
- Negative Sentiment: IRIDEX’s latest reported quarter remains a fundamental concern. The company posted a $0.07-per-share loss versus a $0.01 expected loss and revenue of $12.57 million versus the $13.59 million consensus estimate. Analysts expect a full-year loss of approximately $0.12 per share.
Hedge Funds Weigh In On IRIDEX
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. United Capital Financial Advisors LLC acquired a new stake in shares of IRIDEX in the 2nd quarter valued at approximately $41,000. Weber Capital Management LLC ADV acquired a new position in shares of IRIDEX in the 2nd quarter valued at $206,616. Diversify Advisory Services LLC bought a new stake in shares of IRIDEX in the 2nd quarter valued at $30,000. Bank of New York Mellon Corp acquired a new stake in IRIDEX during the 2nd quarter worth $29,000. Finally, Renaissance Technologies LLC lifted its holdings in IRIDEX by 6.7% during the first quarter. Renaissance Technologies LLC now owns 396,627 shares of the medical equipment provider’s stock worth $401,000 after acquiring an additional 25,067 shares in the last quarter. Institutional investors own 20.10% of the company’s stock.
About IRIDEX
IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.
The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.
Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.
Featured Stories
- Five stocks we like better than IRIDEX
- Want Private-Market Access to Kalshi and Polymarket? Try This ETF
- Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds
- PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value
- Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.
